



Filamon Makes Progress in Developing an Oral Anti-Inflammatory Drug for Eye Diseases

- Filamon achieves a preclinical milestone with experimental anti-inflammatory drug, BETA-TT8, achieving high drug levels in the eye and brain following oral dosing
- BETA-TT8 opens the door to treating inflammatory conditions of the eye and brain, addressing a significant unmet need in ageing populations
- Developed with support from a ~A\$4.8 million Federal Government grant in partnership with UNSW to design a more effective and patient-friendly treatment of wet AMD.

16 June 2025, Sydney, Australia. Filamon Limited ("Filamon"), a clinical-stage Australian drug development company, is pleased to announce important pre-clinical data for its experimental oral, anti-inflammatory drug, BETA-TT8.

The data generated by a global contract research organisation confirmed BETA-TT8's ability to cross both the blood-brain and blood-eye barriers, achieving high drug levels in both tissues.




Figure 1: Levels of BETA-TT8 over 24 hours in mouse blood, eye and brain following a single oral dose

Data shows that BETA-TT8 readily accesses both brain and eye tissue achieving levels at least as high as blood levels and persisting in both tissues with a mean half-life of 9.5 hours. The report also noted that the drug was readily (45%) absorbed orally in mice.

Filamon CEO, Dr Graham Kelly, commented: "We are delighted by these preliminary results because over 98% of all human drugs are prevented from entering the brain and eye via the blood, effectively depriving many patients with inflammatory conditions of meaningful long-term treatment. In the case of the eye, anti-inflammatory drugs need to be injected directly into the eyeball."



“We see BETA-TT8 as a potential breakthrough in the treatment of a wide range of acute and chronic inflammatory conditions affecting the eye and brain and the findings reported today give us the confidence to move forward with BETA-TT8 into humans, starting with the eye and the disease, wet AMD, the major cause of blindness in the elderly.”

The blood vessels of the brain and eye play an important protective role by excluding around 98% of systemically administered drugs. In the case of chronic inflammatory eye conditions such as macular degeneration and geographic atrophy, current treatments require regular injections directly into the eyeball (intravitreal injection) because of this barrier.

BETA-TT8 is the product of a ~\$4.8M collaboration between Filamon and University of New South Wales (UNSW), largely funded by the Federal Government. The grant was awarded to develop a more effective, safer, cost-effective and patient-friendly treatment for wet age-related macular degeneration, the leading cause of blindness in older Australians and a growing health burden due to the ageing population. The funding extends until early 2027 and is expected to cover the cost of advancing BETA-TT8 to human clinical trials, after which Filamon assumes financial responsibility for the drug's ongoing development.

BETA-TT8 is fully owned by Filamon and is the subject of a PCT patent application for use as an anti-inflammatory across all forms of inflammatory disease, notably including inflammatory conditions of the central nervous system, comprising the brain, spinal cord, inner ear and eye.

About BETA-TT8

BETA drugs are Type 4 kinase inhibitors of MEK1/ERK1. Transcription factors impacted include AP-1, FosB, Δ FosB, cJun and NF- κ B, in turn impacting a wide range of genes involved in inflammation, angiogenesis and immune cell activity.

An earlier BETA drug was tested in an animal model of wet AMD by a large CRO and shown to have outperformed aflibercept, the current standard of care drug. BETA-TT8 has been designed with superior drug-like qualities compared to that earlier BETA drug.

BETA-TT8 is being developed as a treatment for wet (neovascular) age-related macular degeneration and diabetic macular oedema, with both oral and topical (eyedropper) dosage forms under development.

About Filamon Limited

Filamon is an Australian, public, unlisted drug development company focused on the development of next generation anti-inflammatory drugs for age-related chronic inflammatory diseases. The target market is degenerative diseases accounting for most hospitalisations and deaths in developed countries. The Company's drug pipeline is derived from three technology platforms targeting complex signalling pathways previously considered undruggable because of their importance to cell function.

The current target indications are late-stage solid cancers, ophthalmic diseases including wet AMD and dry AMD, and neurological diseases associated with neuroinflammation including Alzheimer's disease and other dementias.

**Contact**

Media enquiries

Matthew Wright

NWR Communications

T: +61 451 896 420

E: matt@nwrcommunications.com.au

Investor/Corporate enquiries

corporate@filamon.com

www.filamon.com